Lv7
4520 积分 2020-07-17 加入
Implementation of the principles of the 3Rs of animal testing at CDER: Past, present and future
3天前
求助中
An industry perspective on the FDA modernization act 2.0/3.0: Potential next steps for sponsors to reduce animal use in drug development
3天前
已完结
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
3天前
求助中
Female glucagon receptor knockout mice are prone to steatosis but resistant to weight gain when fed a MASH‐promoting GAN diet and a high‐fat diet
4天前
已完结
Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway
5天前
已完结
Determination of the Number of Tissue Groups of Kinetically Distinct Transit Time in Whole-Body Physiologically Based Pharmacokinetic (PBPK) Models I: Theoretical Consideration of Bottom-Up Approach of Lumping Tissues in Whole-Body PBPK
8天前
已完结
Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models
11天前
已完结
PK/PD Approaches
11天前
已完结
FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression
14天前
已完结
An Integrated AI‐PBPK Platform for Predicting Drug In Vivo Fate and Tissue Distribution in Human and Inter‐Species Extrapolation
16天前
已完结
皖公网安备34019202002308
